Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes
San Francisco, CA
Friday, October 16, 2015
8:00 AM – 4:00 PM
The most important advances in HCV research and clinical care in the last year will be summarized and presented by leading experts in the field, in a 1-day CME course setting. Click here to view the agenda.
Assessment of Needs
The full-day advanced CME course will focus on hepatitis C virus (HCV) infection. Rapid advances in HCV disease management, with available treatments capable of curing HCV, will require the ongoing attention of practitioners involved in HCV medicine.
On completion of the course, participants will be able to:
- Design effective HCV treatment regimens
- Evaluate current treatment options in specific patient populations, such as patients with cirrhosis, patients with HIV/HCV coinfection, transplant recipients, patients with acute HCV infection, patients with renal disease, and those with HCV genotype 3 infection
- Describe the current data on available HCV treatments, the emergence of drug resistance, and investigational and other treatment regimens
- Describe the effects of HCV on the liver and general approaches for treating infection in those with end-stage liver disease that the nonhepatologist should know
- Distinguish compensated versus decompensated cirrhosis in terms of when complex patients should be referred to a hepatologist
- Describe potential drug-drug interactions in HIV/HCV-coinfected patients
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Who Should Attend
This full-day advanced CME course is designed for clinicians who have a solid understanding of the basics of HCV transmission, testing, and management, and who are actively treating patients with HCV infection.
This activity is also relevant for other practitioners including nurse practitioners and other nursing professionals, physician assistants, and pharmacists.
Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms) must contact the IAS–USA regarding registration procedures.
Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed a week after the course minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 6.75 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 6.75 hours (0.675 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-15-279-L01-P
This course is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Food and beverages at IAS-USA events are purchased with registration fees, not with grant support money. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Merck & Co, Inc